Sihe Zhang

Changhongjie, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling.

CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling.

Journal: Cell death & disease

Published: April 02, 2026

Erratum: Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma: Erratum.

Erratum: Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma: Erratum.

Journal: International journal of biological sciences

Published: January 05, 2026

Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity.

Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity.

Journal: Pharmacological research

Published: November 03, 2025

Sulfatase-responsive phase-separating peptide coacervates target stress granules to reverse sorafenib resistance in hepatocellular carcinoma.

Sulfatase-responsive phase-separating peptide coacervates target stress granules to reverse sorafenib resistance in hepatocellular carcinoma.

Journal: Acta biomaterialia

Published: October 10, 2025

Gelatin Zymography: Principle, Method and Application in Cancer Research.

Gelatin Zymography: Principle, Method and Application in Cancer Research.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 10, 2025

The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond.

The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: December 11, 2024

Tumor microenvironment-responsive cell-penetrating peptides: Design principle and precision delivery.

Tumor microenvironment-responsive cell-penetrating peptides: Design principle and precision delivery.

Journal: Colloids and surfaces. B, Biointerfaces

Published: May 08, 2024

Antibody drugs targeting SARS-CoV-2: Time for a rethink?

Antibody drugs targeting SARS-CoV-2: Time for a rethink?

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 14, 2024

Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity.

Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity.

Journal: MedComm

Published: November 26, 2023

Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.

Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.

Journal: International journal of biological sciences

Published: November 14, 2023

Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy.

Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy.

Journal: Acta biomaterialia

Published: September 04, 2023

GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca2+ nanoparticles underlies distinct gene therapy effect in ovarian cancer.

GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca2+ nanoparticles underlies distinct gene therapy effect in ovarian cancer.

Journal: Journal of nanobiotechnology

Published: March 07, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026